Building a model of interaction at the NK-2 receptors: Polycondensed heterocycles containing the pyrimidoindole skeleton

European Journal of Medicinal Chemistry

Volumn 32, Issue 12, 1998, Pages 973-985

  Santagati, A ^a   Longmore, J ^b   Guccione, S ^a   Langer, T ^c   Tonnel, E ^c,e   Modica, M ^a   Santagati, M ^a   Monsu Scolaro L ^d   Russo, F ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIV MONTPELLIER   (France)

Author keywords

Graphic computer model; Indole derivatives; Neurokinin receptors

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; INDOLE DERIVATIVE; NEUROKININ 2 RECEPTOR;

ARTICLE; BINDING AFFINITY; COMPUTER MODEL; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HYPOTHESIS; IN VITRO STUDY; INFRARED SPECTROPHOTOMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS;

EID: 0031472915     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(97)89641-9     Document Type: Article

References (43)

1. 1 Clapham DE (1996) Nature 379, 297-299
2. 2 Savarese TM, Fraser MC (1992) Biochem J 283, 1-19
3. 3 Hilbert MF, Trumpp-Kallmeyer S, Hoflack J, Bruinvels A (1993) Trends Pharmacol Sci 14, 7-12
4. 4 Saunders J (1993) Drug Des Discovery 9, 213-220
5. 5 Fong TM, Cascieri MA, Yu H, Bansal H, Swain C, Strader CD. Nature (1993) 362, 350-353
6. 6 Kocis P (1995) Drugs Future 20 (2), 173-183
7. 7 Natsugari H, Ikeura Y, Kiyota Y, Ishichi Y, Ishimaru T, Saga O, Shirafuji H, Tanaka T, Kamo I, Doi T, Otsuka M (1995) J Med Chem 38, 3106-3120
8. 8 Evans BE, Bock MG, Rittle KE, Di Pardo RM, Whitter WL, Veber DF, Anderson PS, Freidinger RM (1986) Proc Natl Acad Sci USA 83, 4918-4922
9. 9 Rees DC (1994) Curr Med Chem 1, 145-148
10. 10 Pradier L, Habt-Ortoli E, Emile L, Le Guerin J, Loquet I, Bock MD, Clot J, Mercken L, Fardin V, Garret C, Mayaux JF (1995) Mol Pharmacol 47, 314-321
11. 11 Russo F, Romeo G, Guccione S, De Blasi A (1991) J Med Chem 34, 1850-1854
12. 12 Russo F, De Blasi A, Ambrosini G, Romeo G, Guccione S (1993) Eur J Med Chem 28, 499-504
13. 13 Romeo G, Russo F, Guccione S, Barbarulo D, De Blasi A (1995) Il Farmaco 50 (6), 471-477
14. 14 Modica M, Santagati M, Russo F, Parotti L, De Gioia L, Sclvaggini C, Salmona M, Mennini T (1997) J Med Chem 40, 574-585
15. 15 Guccione S, Modica M, Longmore J, Shaw D, Uccello Barretta G, Santagati A, Santagati M, Russo F (1996) Bioorg Med Chem Lett 6, 59-64 and references therein
16. 16 Lazareno S, Birsdall JM (1995) Mol Pharmacol 48, 362-378
17. 17 Longmore J, Swain CJ, Hill RG (1995) Drugs News Perspectives 8, 5-23
18. 18 Maggi CA, Patacchini R, Rovero P, Giachetti A (1993) J Autonom Pharmacol 13, 23-93
19. 19 Waitling KJ, Krause JE (1993) Trends Pharmacol Sci 14, 81-84
20. 20 Yokota Y, Azokawa C, Ohkubo H, Nakanishi S (1992) Embo J 11, 3585-3591
21. 21 Barnes PJ (1990) Arch Int Pharmacodyn 303, 67-82
22. 22 Lundberg JM (1990) Arch Int Pharmacodyn 303, 9-19
23. 23 Fong TM, Strader CD (1994) Med Res Rev 14, 387-399
24. 24 Hagiwara D, Miyake H, Morimoto H, Murai M, Fujii T, Matsuo M (1992) J Med Chem 35, 3184-3191
25. 25 Russo F, Romeo G, Guccione S, Bousquet E (1990) Pharmazie 45, 242-244 and references therein
26. 26 Russo F, Guccione S, Santagati NA, Santagati A, Caruso A, Leone MG, Felice A, Attaguile G, Amico Roxas M (1988) Il Farmaco Ed Sc 43, 409-420 and references therein
27. 27 Unangst PC (1983) J Heterocyclic Chem 20, 495-499
28. 28 Frank RL, Smith PV (1948) Organic Synthesis (Snyder HR, ed) John Wiley, New York, Vol 28, pp 89-91
29. 29 Douglass IB, Dains FB (1934) Am Soc 56, 1408-1409
30. 30 Bellamy LJ (1959) The Infrared Spectra of Complex Molecules, John Wiley, New York
31. 31 Fleming I (1976) Frontier Orbitals and Organic Chemical Reactions, John Wiley, New York
32. 32 Cramer III RD, Patterson DE, Bunce JD (1988) J Am Chem Soc 110, 5959-5967
33. 33 Brown JR, Clegg SP, Ewan GB, Hagan RM, Ireland SJ, Jordan CC, Porter B, Ross BC, Ward P (1989) Molecular Recognition: Chemical and Biochemical Problems, Royal Society of Chemistry Special Publication 78 (Roberts SM, ed). Royal Society of Chemistry, Letchward
34. 34 Portoghese PS, Moe ST, Takemori AE (1993) J Med Chem 36, 2572-2574 and references therein
35. 35 Verdonk ML, Boks GJ, Kooijman H, Kanters JA, Kroon J (1993) J Comput Aided Mol Design 7, 173-182
36. 36 Marshall GR, Barry CD, Bosshard HE, Dammkoehler RA, Dunn DA (1979) The conformational parameter in drug design: the active analog approach. In: Computer-Assisted Drug Design (Olson EC and Christofferson RE, eds), ACS Symposium Series. Vol 112, American Chemical Society, Washington DC, 205-226
37. 37 Marshall GR (1993) Binding-site modelling of unknown receptors. In: 3D QSAR in Drug Design: Theory, Methods and Applications (Kubinyi H, ed), ESCOM, Leiden, 80-116
38. 38 Sybyl 6.2 (1995) Tripos Ass, St Louis, MO 63144, USA
39. 39 MOPAC 6.0, QCPE #455, QCPE, Bloomington, IN 47405, USA
40. 40 Thibaut U (1993) Applications of CoMFA and related 3D QSAR approaches. In: 3D QSAR in Drug Design: Theory, Methods and Applications (Kubinyi H, ed), ESCOM, Leiden, 661-696
41. 41 Gasteiger J, Marsili M (1980) Tetrahedron 36, 3219-3288
42. 42 Razzaque Z, Longmore J (1993) Neuropeptides 25, 169-174
43. 43 Longmore J, Razzaquee Z, Shaw D, Hill RG (1994) Br J Pharmacol 112, 176-178